RU2009122368A - Производные пиразола в качестве промежуточных для получения соединений, используемых как лекарственные средства для лечения острых или хронических дегенераций нейронов - Google Patents
Производные пиразола в качестве промежуточных для получения соединений, используемых как лекарственные средства для лечения острых или хронических дегенераций нейронов Download PDFInfo
- Publication number
- RU2009122368A RU2009122368A RU2009122368/04A RU2009122368A RU2009122368A RU 2009122368 A RU2009122368 A RU 2009122368A RU 2009122368/04 A RU2009122368/04 A RU 2009122368/04A RU 2009122368 A RU2009122368 A RU 2009122368A RU 2009122368 A RU2009122368 A RU 2009122368A
- Authority
- RU
- Russia
- Prior art keywords
- benzyloxy
- ethyl
- pyrazole
- phenylpyrazol
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение формулы (II), выбранное из следующих соединений: ! 3-(3-Бензилокси-4-фенилпиразол-1-ил)-1-азабицикло-[2.2.2]-октан; ! 1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]пергидроазепин; ! 1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-метил-пиперидин; ! 1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-4-фтор-пиперидин; ! 1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-3-метил-пиперидин; ! 7-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-7-азабицикло-[2.2.1]гептан; ! 2-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-азабицикло[2.2.2]октан; ! 2-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-азабицикло[2.2.1]гептан; ! [2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диметиламин дигидрохлорид; ! [3-(3-Бензилокси-4-фенилпиразол-1-ил)пропил]диметиламин дигидрохлорид; ! [3-(3-Бензилокси-4-фенилпиразол-1-ил)пропил]диметиламин оксалат; ! (2S,6R)-1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2,6-диметилпиперидин дигидрохлорид; ! (2S,6R)-1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2,6-диметилпиперидин; ! [2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диэтилиламин дигидрохлорид; ! [2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диэтиламин оксалат; ! [2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диизопропиламин дигидрохлорид; ! [2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диизопропиламин оксалат; ! 3-Бензилокси-4-фенил-1-(2-пирролидин-1-илэтил)-1H-пиразол дигидрохлорид; ! 3-Бензилокси-4-фенил-1-(2-пирролидин-1-илэтил)-1H-пиразол оксалат; ! {2-[3-(Циклогекс-2-енилокси)-4-фенилпиразол-1-ил]-1-метил-этил}диметиламин; ! 3-(3-Бензилокси-4-фенилпиразол-1-илметил)-1-метил-пиперидин; ! 1-{2-[3-(Циклогекс-2-енилокси)-5-метил-4-фенилпиразол-1-ил]этил}пиперидин; ! {2-[3-Бензилокси-4-(3-нитрофенил)пиразол-1-ил]этил}диметилиламин; ! N-{3-[3-Бензилокси-1-(2-диметиламиноэтил)-1H-пиразол-4-ил]фенил}ацетамид; ! 3-[3-Бензило�
Claims (3)
1. Соединение формулы (II), выбранное из следующих соединений:
3-(3-Бензилокси-4-фенилпиразол-1-ил)-1-азабицикло-[2.2.2]-октан;
1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]пергидроазепин;
1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-метил-пиперидин;
1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-4-фтор-пиперидин;
1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-3-метил-пиперидин;
7-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-7-азабицикло-[2.2.1]гептан;
2-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-азабицикло[2.2.2]октан;
2-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2-азабицикло[2.2.1]гептан;
[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диметиламин дигидрохлорид;
[3-(3-Бензилокси-4-фенилпиразол-1-ил)пропил]диметиламин дигидрохлорид;
[3-(3-Бензилокси-4-фенилпиразол-1-ил)пропил]диметиламин оксалат;
(2S,6R)-1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2,6-диметилпиперидин дигидрохлорид;
(2S,6R)-1-[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]-2,6-диметилпиперидин;
[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диэтилиламин дигидрохлорид;
[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диэтиламин оксалат;
[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диизопропиламин дигидрохлорид;
[2-(3-Бензилокси-4-фенилпиразол-1-ил)этил]диизопропиламин оксалат;
3-Бензилокси-4-фенил-1-(2-пирролидин-1-илэтил)-1H-пиразол дигидрохлорид;
3-Бензилокси-4-фенил-1-(2-пирролидин-1-илэтил)-1H-пиразол оксалат;
{2-[3-(Циклогекс-2-енилокси)-4-фенилпиразол-1-ил]-1-метил-этил}диметиламин;
3-(3-Бензилокси-4-фенилпиразол-1-илметил)-1-метил-пиперидин;
1-{2-[3-(Циклогекс-2-енилокси)-5-метил-4-фенилпиразол-1-ил]этил}пиперидин;
{2-[3-Бензилокси-4-(3-нитрофенил)пиразол-1-ил]этил}диметилиламин;
N-{3-[3-Бензилокси-1-(2-диметиламиноэтил)-1H-пиразол-4-ил]фенил}ацетамид;
3-[3-Бензилокси-1-(2-диметиламиноэтил)-1H-пиразол-4-ил]фенилиламин;
{2-[3-Бензилокси-4-(4-нитрофенил)пиразол-1-ил]этил}диметиламин;
{2-[3-Бензилокси-4-(4'-фторбифенил-3-ил)пиразол-1-ил]этил}диметиламин;
{2-[3-Бензилокси-4-(3-бромфенил)пиразол-1-ил]этил}-диметиламин;
{2-[3-Бензилокси-4-бифенил-3-илпиразол-1-ил]этил}-диметиламин;
{2-[3-Бензилокси-4-(4'-фторбифенил-4-ил)-пиразол-1-ил]-этил}диметиламин;
{2-[3-Бензилокси-4-(4-бромфенил)пиразол-1-ил]этил}-диметиламин;
2-[3-(Циклогекс-2-енилокси)-1-(2-пиперидин-1-илэтил)-1H-пиразол-4-ил]пиридин;
4-[3-Бензилокси-1-(2-пиперидин-1-илэтил)-1H-пиразол-4-ил]пиридин;
3-Бензилокси-4-(4-фторфенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(4-трифторметоксифенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
1-{2-[3-(Циклогекс-2-енилокси)-4-фенилпиразол-1-ил]-1-метил-этил}пиперидин;
3-Бензилокси-4-(5-хлортиофен-2-ил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(3-метоксифенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(2-метоксифенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
1-{2-[3-Бензилокси-4-(4-метоксифенил)пиразол-1-ил]-этил}пиперидин;
1-{2-[3-Бензилокси-4-(3-фторфенил)пиразол-1-ил]-этил}пиперидин;
1-{2-[3-Бензилокси-4-(3-трифторметилфенил)пиразол-1-ил]этил}пиперидин;
3-[3-Бензилокси-1-(2-пиперидин-1-илэтил)-1H-пиразол-4-ил]пиридин;
1-{2-[3-Бензилокси-4-(4-хлорфенил)пиразол-1-ил]-этил}пиперидин;
1-{2-[3-Бензилокси-4-(3-хлорфенил)пиразол-1-ил]-этил}пиперидин;
1-{2-[3-Бензилокси-4-(2-фторфенил)пиразол-1-ил]-этил}пиперидин;
1-{2-[3-Бензилокси-4-(2-хлорфенил)пиразол-1-ил]-этил}пиперидин;
3-[3-Бензилокси-4-(4-хлорфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
3-[3-Бензилокси-4-(3-хлорфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
3-[3-Бензилокси-4-(3-фторфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
3-Бензилокси-1-(1-метилпирролидин-3-ил)-4-фенил-1H-пиразол;
3-Бензилокси-1-[2-(1-метилпирролидин-2-ил)этил]-4-фенил-1H-пиразол;
3-Бензилокси-4-фенил-1-(пирролидин-3-ил)-1H-пиразол дигидрохлорид;
3-Бензилокси-1-[(1-метилпирролидин-2-(S)-ил)-метил]-4-фенил-1H-пиразол;
3-Бензилокси-1-((2R)-1-метилпирролидин-2-илметил)-4-фенил-1H-пиразол;
3-Бензилокси-4-фенил-1-((2R)-пирролидин-2-илметил)-1H-пиразол гидрохлорид;
3-Бензилокси-4-фенил-1-(пиперидин-3-ил)-1H-пиразол гидрохлорид;
3-Бензилокси-1-(1-метилпиперидин-2-илметил)-4-фенил-1H-пиразол;
3-Бензилокси-1-(1-метилaзепан-3-ил)-4-фенил-1H-пиразол;
3-Бензилокси-4-фенил-1-(2-пиперидин-1-илэтил)-1H-пиразол оксалат;
3-Бензилокси-4-(3,4-дихлорфенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(4-бромфенил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(1H-индол-5-ил)-1-(2-пиперидин-1-илэтил)-1H-пиразол;
3-Бензилокси-4-(5-бромтиофен-2-ил)-1-(2-пиперидин-1-ил-этил)-1H-пиразол оксалат;
3-Бензилокси-4-(4-метилфенил)-1-(2-пиперидин-1-илэтил]-1H-пиразол оксалат;
1-(1-Азабицикло[2.2.2]окт-3-ил)-3-бензилокси-4-(5-хлор-тиофен-2-ил)-1H-пиразол;
2-(3-Бензилокси-4-фенилпиразол-1-илметил)-1-аза-бицикло[2.2.2]октан;
1-[2-(4-Бензо[b]тиофен-2-ил-3-бензилoксипиразол-1-ил)-этил]пиперидин;
1-[2-(3-Бензилокси-4-тиофен-3-илпиразол-1-ил)этил]-пиперидин;
4-[3-Бензилокси-1-(2-пиперидин-1-илэтил)-1H-пиразол-4-ил]бензамид;
3-[3-Бензилокси-1-(2-пиперидин-1-илэтил)-1H-пиразол-4-ил]-бензамид;
(+)-3-(3-Бензилокси-4-фенилпиразол-1-ил)-1-азабицикло-[2.2.2]октан
(-)-3-(3-Бензилокси-4-фенилпиразол-1-ил)-1-азабицикло-[2.2.2]октан;
(-)-3-(3-Бензилокси-4-фенилпиразол-1-илметил)-1-азабицикло-[2.2.2]октан;
(+)-3-(3-Бензилокси-4-фенилпиразол-1-илметил)-1-азабицикло[2.2.2]октан;
3-[3-Бензилокси-4-(4-хлорфенил)пиразол-1-илметил]-1-азабицикло[2.2.2]октанборан;
(+)-3-[3-Бензилокси-4-(4-хлорфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
(-)-3-[3-Бензилокси-4-(4-хлорфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
(+)-3-[3-Бензилокси-4-(4-фторфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан;
(-)-3-[3-Бензилокси-4-(4-фторфенил)пиразол-1-ил]-1-азабицикло[2.2.2]октан; и
3-[3-(Циклогекс-2-енилокси)-4-пиридин-2-ил-пиразол-1-ил]-1-азабицикло[2.2.2]октан.
2. Соединение формулы (III), выбранное из следующих соединений:
3-Метокси-4-фенилпиразол;
3-Бензилокси-4-фенилпиразол;
3-Дифторметокси-4-фенил-1H-пиразол;
3-(Циклогекс-2-енилокси)-4-фенил-1H-пиразол;
3-(Циклогекс-2-енилокси)-5-метил-4-фенил-1H-пиразол;
3-Бензилокси-4-(3-нитрофенил)-1H-пиразол;
3-Бензилокси-4-(4-нитрофенил)-1H-пиразол;
3-Бензилокси-4-(3-бромфенил)-1H-пиразол;
3-Бензилокси-4-(4-бромфенил)-1H-пиразол;
2-[3-(Циклогекс-2-енилокси)-1H-пиразол-4-ил]пиридин;
4-(3-Бензилокси-1H-пиразол-4-ил)пиридин;
3-Бензилокси-4-(4-трифторметоксифенил)-1H-пиразол;
4-Фенил-1H-пиразол;
3-Бензилокси-4-(5-хлортиофен-2-ил)-1H-пиразол;
3-Бензилокси-4-(3-метоксифенил)-1H-пиразол;
3-Бензилокси-4-(2-метоксифенил)-1H-пиразол;
3-Бензилокси-4-(4-хлорфенил)-1H-пиразол;
3-Бензилокси-4-(3-хлорфенил)-1H-пиразол;
3-Бензилокси-4-(2-фторфенил)-1H-пиразол;
3-Бензилокси-4-(2-хлорфенил)-1H-пиразол;
3-Бензилокси-4-(3,4-дихлорфенил)-1H-пиразол;
3-Бензилокси-4-(4-бромфенил)-1H-пиразол;
3-Бензилокси-4-(5-бромтиофен-2-ил)пиразол;
4-(4-Цианофенил)-1H-пиразол;
4-(2-Метоксифенил)-1H-пиразол;
3-Бензилокси-4-(4-метилфенил)-1H-пиразол;
4-(3,5-Дифторфенил)-1H-пиразол;
4-Бензо[b]тиофен-2-ил-3-бензилокси-1H-пиразол;
3-Бензилокси-4-тиофен-3-ил-1H-пиразол;
4-(3-Бензилокси-1H-пиразол-4-ил)бензамид;
3-(3-Бензилокси-1H-пиразол-4-ил)бензамид;
3-Бензилокси-4-(4-фторфенил)-1H-пиразол;
4-(4-Хлорфенил)-1H-пиразол; и
4-(3-Хлор-4-метоксифенил)-1H-пиразол.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0313775 | 2003-11-25 | ||
FR0313775A FR2862647B1 (fr) | 2003-11-25 | 2003-11-25 | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122553/04A Division RU2376290C2 (ru) | 2003-11-25 | 2004-11-22 | Производные пиразола в качестве лекарственных средств для лечения заболеваний, возникающих вследствие дисфункции никотиновых рецепторов альфа7 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2009122368A true RU2009122368A (ru) | 2010-12-20 |
Family
ID=34531236
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122553/04A RU2376290C2 (ru) | 2003-11-25 | 2004-11-22 | Производные пиразола в качестве лекарственных средств для лечения заболеваний, возникающих вследствие дисфункции никотиновых рецепторов альфа7 |
RU2009122368/04A RU2009122368A (ru) | 2003-11-25 | 2009-06-10 | Производные пиразола в качестве промежуточных для получения соединений, используемых как лекарственные средства для лечения острых или хронических дегенераций нейронов |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006122553/04A RU2376290C2 (ru) | 2003-11-25 | 2004-11-22 | Производные пиразола в качестве лекарственных средств для лечения заболеваний, возникающих вследствие дисфункции никотиновых рецепторов альфа7 |
Country Status (31)
Country | Link |
---|---|
US (2) | US7524838B2 (ru) |
EP (1) | EP1689720B1 (ru) |
JP (1) | JP4833078B2 (ru) |
KR (1) | KR20060123193A (ru) |
CN (2) | CN102174017A (ru) |
AR (1) | AR046632A1 (ru) |
AT (1) | ATE428699T1 (ru) |
AU (1) | AU2004293214B2 (ru) |
BR (1) | BRPI0416926A (ru) |
CA (1) | CA2544519A1 (ru) |
CY (1) | CY1110333T1 (ru) |
DE (1) | DE602004020660D1 (ru) |
DK (1) | DK1689720T3 (ru) |
ES (1) | ES2325446T3 (ru) |
FR (1) | FR2862647B1 (ru) |
HR (1) | HRP20090391T1 (ru) |
IL (1) | IL175539A0 (ru) |
MA (1) | MA28147A1 (ru) |
MY (1) | MY141218A (ru) |
NO (1) | NO20062954L (ru) |
NZ (1) | NZ548071A (ru) |
PL (1) | PL1689720T3 (ru) |
PT (1) | PT1689720E (ru) |
RS (1) | RS50836B (ru) |
RU (2) | RU2376290C2 (ru) |
SG (1) | SG131945A1 (ru) |
SI (1) | SI1689720T1 (ru) |
TW (1) | TWI343811B (ru) |
UY (1) | UY28635A1 (ru) |
WO (1) | WO2005051917A1 (ru) |
ZA (2) | ZA200604051B (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
BR122015028990B8 (pt) * | 2007-04-03 | 2017-12-26 | Du Pont | composto, composições fungicidas e método de controle de doenças das plantas |
BRPI0814294A2 (pt) * | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
AU2008313776B2 (en) | 2007-10-18 | 2013-12-05 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles |
CA2714662C (en) | 2008-03-19 | 2016-05-10 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators |
CL2009001125A1 (es) | 2008-05-09 | 2011-02-11 | Janssen Pharmaceutica Nv | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. |
EP2151434A1 (en) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Alkoxypyrazoles and the process for their preparation |
US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
JP5636428B2 (ja) * | 2009-09-17 | 2014-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 置換n−フェニル−1−(4−ピリジニル)−1h−ピラゾル−3−アミン類 |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
WO2011041154A1 (en) * | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
JP5847813B2 (ja) | 2010-06-23 | 2016-01-27 | シマベイ セラピューティクス, インコーポレーテッド | 5−エチル−2−{4−[4−(4−テトラゾル−1−イル−フェノキシメチル)−チアゾール−2−イル]−ピペリジン−1−イル}−ピリミジンの組成物 |
BR102012024778A2 (pt) * | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
JP2016535097A (ja) * | 2013-11-08 | 2016-11-10 | アイティーオス セラペウティクス | 4−(インドール−3−イル)−ピラゾール誘導体、医薬組成物および使用のための方法 |
US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
CA2939164A1 (en) | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
MD20160118A2 (ru) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Пирролидин-2,5-дионовые производные, фармацевтические композиции и способы применения в качестве ингибиторов IDO1 |
EP3263565B1 (en) * | 2015-02-27 | 2019-06-26 | Toray Industries, Inc. | Cyclic amine derivative and pharmaceutical use thereof |
US9873690B2 (en) | 2015-03-17 | 2018-01-23 | Pfizer Inc | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
CA2994917A1 (en) | 2015-08-10 | 2017-02-16 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
KR102625861B1 (ko) * | 2016-06-28 | 2024-01-17 | 삼성디스플레이 주식회사 | 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자 |
KR20190035752A (ko) | 2016-08-03 | 2019-04-03 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | 염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물 |
CN109563072B (zh) * | 2016-08-26 | 2021-05-11 | 东丽株式会社 | 环状胺衍生物的结晶及其医药用途 |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
EP4069685A1 (en) * | 2019-12-02 | 2022-10-12 | F. Hoffmann-La Roche AG | Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2014831A1 (en) | 1968-08-01 | 1970-04-24 | Sogeras | Quinuclidinyl and quinuclidinylalkyl ethers with cholino - lytic, antihistaminic and neurosedative activity |
EP0427390B1 (en) * | 1989-10-07 | 1996-03-27 | Beecham Group Plc | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them |
WO1992021339A1 (en) * | 1991-05-29 | 1992-12-10 | Abbott Laboratories | Isoxazole and isothiazole compounds that enhance cognitive function |
IE922270A1 (en) * | 1991-07-26 | 1993-01-27 | Akzo Nv | Pyrazole derivatives |
GB9500580D0 (en) * | 1995-01-12 | 1995-03-01 | Merck Sharp & Dohme | Therapeutic agents |
EP1002871A1 (en) | 1998-11-17 | 2000-05-24 | Eidgenössische Technische Hochschule (ETH) Zürich | Process for preparing optically active 3-hydroxy-pyrrolidine derivatives by enzymatic hydroxylation |
FR2786188B1 (fr) * | 1998-11-24 | 2002-10-31 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
-
2003
- 2003-11-25 FR FR0313775A patent/FR2862647B1/fr not_active Expired - Fee Related
-
2004
- 2004-11-17 AR ARP040104245A patent/AR046632A1/es unknown
- 2004-11-22 ZA ZA200604051A patent/ZA200604051B/en unknown
- 2004-11-22 BR BRPI0416926-3A patent/BRPI0416926A/pt not_active IP Right Cessation
- 2004-11-22 EP EP04805499A patent/EP1689720B1/fr active Active
- 2004-11-22 SG SG200702985-3A patent/SG131945A1/en unknown
- 2004-11-22 PL PL04805499T patent/PL1689720T3/pl unknown
- 2004-11-22 NZ NZ548071A patent/NZ548071A/en not_active IP Right Cessation
- 2004-11-22 DK DK04805499T patent/DK1689720T3/da active
- 2004-11-22 AU AU2004293214A patent/AU2004293214B2/en not_active Ceased
- 2004-11-22 SI SI200431160T patent/SI1689720T1/sl unknown
- 2004-11-22 DE DE602004020660T patent/DE602004020660D1/de active Active
- 2004-11-22 RS RSP-2009/0321A patent/RS50836B/sr unknown
- 2004-11-22 CN CN2011100312334A patent/CN102174017A/zh active Pending
- 2004-11-22 ES ES04805499T patent/ES2325446T3/es active Active
- 2004-11-22 JP JP2006540522A patent/JP4833078B2/ja not_active Expired - Fee Related
- 2004-11-22 WO PCT/FR2004/002968 patent/WO2005051917A1/fr active Application Filing
- 2004-11-22 CN CNA2004800409520A patent/CN1906172A/zh active Pending
- 2004-11-22 AT AT04805499T patent/ATE428699T1/de active
- 2004-11-22 KR KR1020067010108A patent/KR20060123193A/ko active IP Right Grant
- 2004-11-22 PT PT04805499T patent/PT1689720E/pt unknown
- 2004-11-22 CA CA002544519A patent/CA2544519A1/fr not_active Abandoned
- 2004-11-22 RU RU2006122553/04A patent/RU2376290C2/ru not_active IP Right Cessation
- 2004-11-24 TW TW093136074A patent/TWI343811B/zh not_active IP Right Cessation
- 2004-11-24 MY MYPI20044869A patent/MY141218A/en unknown
- 2004-11-24 US US10/997,736 patent/US7524838B2/en not_active Expired - Fee Related
- 2004-11-25 UY UY28635A patent/UY28635A1/es unknown
-
2006
- 2006-05-02 MA MA28998A patent/MA28147A1/fr unknown
- 2006-05-09 IL IL175539A patent/IL175539A0/en unknown
- 2006-06-23 NO NO20062954A patent/NO20062954L/no not_active Application Discontinuation
-
2007
- 2007-08-16 ZA ZA200706854A patent/ZA200706854B/xx unknown
-
2009
- 2009-02-27 US US12/394,589 patent/US8048893B2/en not_active Expired - Fee Related
- 2009-06-10 RU RU2009122368/04A patent/RU2009122368A/ru not_active Application Discontinuation
- 2009-07-10 HR HR20090391T patent/HRP20090391T1/xx unknown
- 2009-07-14 CY CY20091100737T patent/CY1110333T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009122368A (ru) | Производные пиразола в качестве промежуточных для получения соединений, используемых как лекарственные средства для лечения острых или хронических дегенераций нейронов | |
RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
US6858603B2 (en) | Acetindine derivatives, their preparation and medicaments containing them | |
ES2425347T3 (es) | Derivados de carbamato de 1-alquil-1-azoniabiciclo[2.2.2]octano y su uso como antagonistas de receptores muscarínicos | |
FI114470B (fi) | Uusia allergisten sairauksien hoidossa käyttökelpoisia substituoituja piperidiinejä | |
RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
PE20210402A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
JP2006514942A5 (ru) | ||
RU2007134383A (ru) | Производные 1,5-диарилпиррола, их получение и применение в терапии | |
US6232329B1 (en) | Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles | |
US20080004288A1 (en) | Indazole Sulphonamide Derivatives | |
JP2008513500A5 (ru) | ||
WO2003031435A1 (en) | Pyrazole derivatives as glycine transporter inhibitors | |
AU5523299A (en) | Azetidine derivatives, preparation and medicines containing them | |
CA2487489A1 (en) | Mitotic kinesin inhibitors | |
NZ524904A (en) | Association of the CB1 receptor antagonist and a sibutramine for treating obesity | |
HRP20140030T1 (hr) | Derivati prolina kao inhibitori katepsina | |
JP2015520752A5 (ru) | ||
RU2007127864A (ru) | Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов | |
RU2011111592A (ru) | Замещенные аминоинданы и их аналоги и их применение в фармацевтике | |
SI3075726T1 (en) | DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS | |
RU2007127834A (ru) | Производные 1, 6-замещенного (3r, 6r)-3-(2, 3-дигидро-1н-инден-2-ил)-2, 5-пиперазиндиона в качестве антагонистов рецептора окситоцина для лечения преждевременных родов, дисменореи и эндометриоза | |
AU2008258665B2 (en) | Prolinamide derivatives as NK3 antagonists | |
JP2008516964A5 (ru) | ||
RU2019123319A (ru) | Пиразолопиримидины и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20120710 |